Found 37 Enz. Inhib. hit(s) with all data for entry = 1820 TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt
US Patent
Medifron Dbt
US Patent
Affinity DataKi: 0.100nMAssay Description:The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt
US Patent
Medifron Dbt
US Patent
Affinity DataKi: 0.300nMAssay Description:The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt
US Patent
Medifron Dbt
US Patent
Affinity DataKi: 0.400nMAssay Description:The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt
US Patent
Medifron Dbt
US Patent
Affinity DataKi: 0.600nMAssay Description:The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt
US Patent
Medifron Dbt
US Patent
Affinity DataKi: 0.700nMAssay Description:The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt
US Patent
Medifron Dbt
US Patent
Affinity DataKi: 0.700nMAssay Description:The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt
US Patent
Medifron Dbt
US Patent
Affinity DataKi: 0.700nMAssay Description:The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt
US Patent
Medifron Dbt
US Patent
Affinity DataKi: 1.10nMAssay Description:The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt
US Patent
Medifron Dbt
US Patent
Affinity DataKi: 1.40nMAssay Description:The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt
US Patent
Medifron Dbt
US Patent
Affinity DataKi: 2.30nMAssay Description:The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt
US Patent
Medifron Dbt
US Patent
Affinity DataKi: 2.35nMAssay Description:The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt
US Patent
Medifron Dbt
US Patent
Affinity DataKi: 4.70nMAssay Description:The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt
US Patent
Medifron Dbt
US Patent
Affinity DataKi: 5.20nMAssay Description:The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt
US Patent
Medifron Dbt
US Patent
Affinity DataKi: 5.90nMAssay Description:The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt
US Patent
Medifron Dbt
US Patent
Affinity DataKi: 6.60nMAssay Description:The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt
US Patent
Medifron Dbt
US Patent
Affinity DataKi: 7.5nMAssay Description:The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt
US Patent
Medifron Dbt
US Patent
Affinity DataKi: 9.10nMAssay Description:The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt
US Patent
Medifron Dbt
US Patent
Affinity DataKi: 12.3nMAssay Description:The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt
US Patent
Medifron Dbt
US Patent
Affinity DataKi: 13.8nMAssay Description:The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt
US Patent
Medifron Dbt
US Patent
Affinity DataKi: 17.6nMAssay Description:The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt
US Patent
Medifron Dbt
US Patent
Affinity DataKi: 19.4nMAssay Description:The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt
US Patent
Medifron Dbt
US Patent
Affinity DataKi: 24.6nMAssay Description:The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt
US Patent
Medifron Dbt
US Patent
Affinity DataKi: 27.5nMAssay Description:The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt
US Patent
Medifron Dbt
US Patent
Affinity DataKi: 28.4nMAssay Description:The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt
US Patent
Medifron Dbt
US Patent
Affinity DataKi: 29.8nMAssay Description:The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt
US Patent
Medifron Dbt
US Patent
Affinity DataKi: 29.9nMAssay Description:The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt
US Patent
Medifron Dbt
US Patent
Affinity DataKi: 33.3nMAssay Description:The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt
US Patent
Medifron Dbt
US Patent
Affinity DataKi: 35nMAssay Description:The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt
US Patent
Medifron Dbt
US Patent
Affinity DataKi: 41.9nMAssay Description:The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt
US Patent
Medifron Dbt
US Patent
Affinity DataKi: 43.6nMAssay Description:The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt
US Patent
Medifron Dbt
US Patent
Affinity DataKi: 48.8nMAssay Description:The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt
US Patent
Medifron Dbt
US Patent
Affinity DataKi: 52.6nMAssay Description:The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt
US Patent
Medifron Dbt
US Patent
Affinity DataKi: 60.8nMAssay Description:The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt
US Patent
Medifron Dbt
US Patent
Affinity DataKi: 62.5nMAssay Description:The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt
US Patent
Medifron Dbt
US Patent
Affinity DataKi: 78.4nMAssay Description:The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt
US Patent
Medifron Dbt
US Patent
Affinity DataKi: 96.7nMAssay Description:The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...More data for this Ligand-Target Pair
TargetTransient receptor potential cation channel subfamily V member 1(Homo sapiens (Human))
Medifron Dbt
US Patent
Medifron Dbt
US Patent
Affinity DataKi: 103nMAssay Description:The FLIPR protocol consists of 2 substance additions during a kinetic measurement. First the compounds to be tested (5 μM) are pipetted onto the...More data for this Ligand-Target Pair
